We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+8.26%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$2.1B
AUM Growth
+$165M
Cap. Flow
+$97.9M
Cap. Flow %
4.65%
Top 10 Hldgs %
81.04%
Holding
26
New
2
Increased
12
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$32.6M
2
RDUS
Radius Health, Inc.
RDUS
+$25.3M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$20.6M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$12.8M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.92M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$11.4M
2
IDIX
IDENIX PHARMACEUTICALS INC
IDIX
+$7.54M
3
INVA icon
Innoviva
INVA
+$4.05M
4
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$3.53M
5
GILD icon
Gilead Sciences
GILD
+$1.95M

Sector Composition

Rank Sector Weight
1 Healthcare 85.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$362M 17.22%
4,219,298
-150,000
-3% -$11.4M
GILD icon
2
Gilead Sciences
GILD
$165B
$289M 13.74%
3,488,496
-25,000
-0.7% -$1.95M
INCY icon
3
Incyte
INCY
$25.4B
$235M 11.17%
4,163,790
+30,000
+0.7% +$1.53M
IONS icon
4
Ionis Pharmaceuticals
IONS
$8.93B
$231M 10.98%
6,706,526
+405,000
+6% +$12.8M
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$123B
$133M 6.32%
1,404,445
– –
MDVN
6
DELISTED
MEDIVATION, INC.
MDVN
$116M 5.49%
2,999,412
+80,000
+3% +$2.7M
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
$114M 5.4%
727,428
– –
GEVA
8
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$94.2M 4.47%
898,476
-41,481
-4% -$3.53M
REGN icon
9
Regeneron Pharmaceuticals
REGN
$72.9B
$65.8M 3.13%
233,000
+10,000
+4% +$2.96M
PCYC
10
DELISTED
PHARMACYCLICS INC
PCYC
$65.6M 3.12%
731,542
+95,000
+15% +$8.91M
HALO icon
11
Halozyme
HALO
$9.88B
$57.8M 2.74%
5,846,564
+205,000
+4% +$1.74M
NBIX icon
12
Neurocrine Biosciences
NBIX
$18.2B
$45.8M 2.18%
3,086,552
+90,000
+3% +$1.27M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$38.3B
$39.2M 1.86%
621,288
+150,000
+32% +$8.92M
PBYI icon
14
Puma Biotechnology
PBYI
$398M
$38.1M 1.81%
576,991
+459,000
+389% +$32.6M
IMGN
15
DELISTED
Immunogen Inc
IMGN
$37.5M 1.78%
3,165,816
– –
RDUS
16
DELISTED
Radius Health, Inc.
RDUS
$35.7M 1.7%
+2,745,040
New +$25.3M
INVA icon
17
Innoviva
INVA
$1.6B
$27.8M 1.32%
933,244
-169,067
-15% -$4.05M
AGIO icon
18
Agios Pharmaceuticals
AGIO
$2.08B
$23.2M 1.1%
+506,000
New +$20.6M
CLVS
19
DELISTED
Clovis Oncology, Inc.
CLVS
$23.1M 1.1%
558,188
+70,000
+14% +$3.61M
TSRO
20
DELISTED
TESARO, Inc.
TSRO
$21.9M 1.04%
704,582
+100,000
+17% +$2.67M
INFI
21
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$19.2M 0.91%
1,505,737
+205,000
+16% +$2.14M
ECYT
22
DELISTED
Endocyte, Inc. Common Stock
ECYT
$16.2M 0.77%
2,463,522
– –
ACHN
23
DELISTED
Achillion Pharmaceuticals
ACHN
$13.5M 0.64%
1,779,340
– –
ARIA
24
DELISTED
Ariad Pharmaceuticals Inc
ARIA
– –
-171,517
Closed -$1.38M
IDIX
25
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
– –
-1,250,000
Closed -$7.54M

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q2 2014 Portfolio in Review

As of Q2 2014, BB Biotech held 26 positions worth $2.1B, up 8.5% from $1.94B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

BB Biotech deployed $97.9M of net new capital in Q2 2014, opening 2 new positions and adding to 12 existing holdings. Its largest new stake was Radius Health, Inc.: 2,745,040 shares worth $35.7M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 87% a quarter earlier.

On the sell side, the largest reduction was Celgene Corp, an estimated $11.4M trimmed.

  • BB Biotech's largest Q2 2014 buy was Radius Health, Inc.: 2,745,040 shares worth $35.7M.
  • BB Biotech added most to Puma Biotechnology in Q2 2014, an estimated $32.6M increase.
  • BB Biotech's biggest Q2 2014 reduction was Celgene Corp, cutting an estimated $11.4M.
  • BB Biotech fully exited IDENIX PHARMACEUTICALS INC in Q2 2014, selling an estimated $7.54M.
  • BB Biotech's ten largest holdings make up 81% of its $2.1B portfolio in Q2 2014.
  • BB Biotech opened 2 new positions and closed 2 in Q2 2014.
  • BB Biotech's portfolio value rose 8.5% quarter-over-quarter to $2.1B.

Based on BB Biotech's 13F filing for Q2 2014, filed 7 Aug 2014.